BACKGROUND: Using planar gamma scintigraphy of inhaled radioaerosols, we have developed new analytical methods for assessing homogeneity of aerosol deposition and time-dependent particle clearance on a pixel-by-pixel basis, and applied them to a therapeutic cystic fibrosis (CF) study. METHODS: At baseline and 1 month after beginning treatment with ivacaftor, a cystic fibrosis transmembrane regulator modulator for CF patients with at least one copy of the G551D mutation (n = 13), initial deposition and subsequent mucociliary clearance (MCC) of radiolabeled particles (99mTechnetium-sulfur colloid, 5 μm mass median aerodynamic diameter) inhaled under controlled breathing conditions were measured. RESULTS: Improved homogeneity of deposition, that is, decreased areas of higher and lower particle deposition in the lungs, was observed following ivacaftor treatment. The mean number ratio (NR) of pixels with higher deposition, relative to lung size, decreased from 0.14 to 0.09 (p = 0.003) and mean NR of colder pixels decreased from 0.23 to 0.19 (p = 0.004). Particle clearance was also improved following treatment, with mean MCC through 60 minutes equal to 12% versus 24%, without and with treatment, respectively (p = 0.010). Pixel-level analysis of MCC showed that (1) the fraction of pixels clearing >30% at 60 minutes was increased from 0.13 to 0.32 (p = 0.007); and (2) the fraction of pixels clearing <5% at 60 minutes was decreased from 0.54 to 0.37 (p = 0.014), indicating an overall recruitment of more fast-clearing lung regions with ivacaftor treatment. CONCLUSION: These detailed pixel analyses of deposition and clearance homogeneity may supplement traditional methods that use large regions of interest for assessing efficacy and mechanisms of therapeutic intervention in patients with airways disease.
BACKGROUND: Using planar gamma scintigraphy of inhaled radioaerosols, we have developed new analytical methods for assessing homogeneity of aerosol deposition and time-dependent particle clearance on a pixel-by-pixel basis, and applied them to a therapeutic cystic fibrosis (CF) study. METHODS: At baseline and 1 month after beginning treatment with ivacaftor, a cystic fibrosis transmembrane regulator modulator for CFpatients with at least one copy of the G551D mutation (n = 13), initial deposition and subsequent mucociliary clearance (MCC) of radiolabeled particles (99mTechnetium-sulfur colloid, 5 μm mass median aerodynamic diameter) inhaled under controlled breathing conditions were measured. RESULTS: Improved homogeneity of deposition, that is, decreased areas of higher and lower particle deposition in the lungs, was observed following ivacaftor treatment. The mean number ratio (NR) of pixels with higher deposition, relative to lung size, decreased from 0.14 to 0.09 (p = 0.003) and mean NR of colder pixels decreased from 0.23 to 0.19 (p = 0.004). Particle clearance was also improved following treatment, with mean MCC through 60 minutes equal to 12% versus 24%, without and with treatment, respectively (p = 0.010). Pixel-level analysis of MCC showed that (1) the fraction of pixels clearing >30% at 60 minutes was increased from 0.13 to 0.32 (p = 0.007); and (2) the fraction of pixels clearing <5% at 60 minutes was decreased from 0.54 to 0.37 (p = 0.014), indicating an overall recruitment of more fast-clearing lung regions with ivacaftor treatment. CONCLUSION: These detailed pixel analyses of deposition and clearance homogeneity may supplement traditional methods that use large regions of interest for assessing efficacy and mechanisms of therapeutic intervention in patients with airways disease.
Authors: Martyn F Biddiscombe; Sally N Meah; S Richard Underwood; Omar S Usmani Journal: J Aerosol Med Pulm Drug Deliv Date: 2011-03-31 Impact factor: 2.849
Authors: William D Bennett; Miao Xie; Kirby Zeman; Harry Hurd; Scott Donaldson Journal: J Aerosol Med Pulm Drug Deliv Date: 2014-11-13 Impact factor: 2.849
Authors: William D Bennett; Beth L Laube; Timothy Corcoran; Kirby Zeman; Gail Sharpless; Kristina Thomas; Jihong Wu; Peter J Mogayzel; Joseph Pilewski; Scott Donaldson Journal: J Aerosol Med Pulm Drug Deliv Date: 2013-03-21 Impact factor: 2.849
Authors: Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey Journal: Am J Respir Crit Care Med Date: 2014-07-15 Impact factor: 21.405
Authors: Stephen Newman; William D Bennett; Martyn Biddiscombe; Sunalene G Devadason; Myrna B Dolovich; John Fleming; Sabine Haeussermann; Claudius Kietzig; Philip J Kuehl; Beth L Laube; Knut Sommerer; Glyn Taylor; Omar S Usmani; Kirby L Zeman Journal: J Aerosol Med Pulm Drug Deliv Date: 2012-12 Impact factor: 2.849
Authors: Scott H Donaldson; Beth L Laube; Timothy E Corcoran; Pradeep Bhambhvani; Kirby Zeman; Agathe Ceppe; Pamela L Zeitlin; Peter J Mogayzel; Michael Boyle; Landon W Locke; Michael M Myerburg; Joseph M Pilewski; Brian Flanagan; Steven M Rowe; William D Bennett Journal: JCI Insight Date: 2018-12-20